NYSE:CAI

Cai International Stock News

> Rental & Leasing Services

Buy CAI

*Your capital is at risk

$15.48

-1.04 (-6.30%)

At Close: Jun 03, 2026

Caris Life Sciences to Present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference

08:30am, Friday, 24'th Apr 2026

IRVING, Texas, April 24, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that

Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026

08:30am, Monday, 20'th Apr 2026

IRVING, Texas, April 20, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it wi

Caris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer Center

08:30am, Friday, 17'th Apr 2026

IRVING, Texas, April 17, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced tha

Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients

08:30am, Wednesday, 15'th Apr 2026

Comprehensive molecular profiling paired with biomarker-driven trial matching provides cancer patients with a complete pathway from diagnosis to treatment across more than 600 locations nationwide IRV

Caris Life Sciences: Post-IPO Pullback Creates A Long-Term Buy Opportunity

08:30am, Monday, 13'th Apr 2026

Caris Life Sciences' approach pairs molecular profiling, AI, and large clinico-genomic datasets to support oncology diagnostics, therapy selection, and R&D. Its core platforms are the MI Profile and C

Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients

08:30am, Wednesday, 08'th Apr 2026

Caris AI Insights are proprietary and only available to Caris Life Sciences customers IRVING, Texas, April 8, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, n

Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies

08:30am, Thursday, 02'nd Apr 2026

Ultra-deep Whole Genome and Transcriptome Sequencing provides a more complete workup for myeloid malignancies with clearer, faster diagnostic insight IRVING, Texas, April 2, 2026 /PRNewswire/ -- Cari

Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect

06:00pm, Tuesday, 31'st Mar 2026

Results demonstrate the superiority of Whole Genome Sequencing compared to methylation-based approaches IRVING, Texas, March 31, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, p

Caris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung Cancer

08:30am, Thursday, 26'th Mar 2026

Caris AI Insights are proprietary algorithms only available to Caris Life Sciences customers and not achievable through small panels IRVING, Texas, March 26, 2026 /PRNewswire/ -- Caris Life Sciences�

Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026

08:30am, Wednesday, 25'th Mar 2026

IRVING, Texas, March 25, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced tha

Caris Life Sciences Highlights the Importance of DPYD Testing in Colorectal Cancer During Colorectal Cancer Awareness Month

08:30am, Tuesday, 24'th Mar 2026

Caris reinforces the value of Whole Exome Sequencing and Whole Transcriptome Sequencing testing for cancer patients IRVING, Texas, March 24, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI),

Caris Life Sciences Announces Another Breakthrough Study for GPSai in Identifying and Correcting Misdiagnosis of Cancer Patients

08:30am, Friday, 20'th Mar 2026

Highlighting the critical role of Caris GPSai in improving cancer care IRVING, Texas, March 20, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI

Caris Life Sciences Introduces Powerful New Caris AI Insights to Identify Early Platinum Resistance in Ovarian Cancer

08:30am, Monday, 16'th Mar 2026

Caris AI Insights are proprietary and only available to Caris Life Sciences customers IRVING, Texas, March 16, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric,

Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting

08:30am, Wednesday, 11'th Mar 2026

IRVING, Texas, March 11, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that

Caris Life Sciences Launches a Novel Caris AI Insights Signature to Guide First-Line Therapy Selection and Treatment De-Escalation in Pancreatic Cancer

08:30am, Monday, 09'th Mar 2026

Caris AI Insights are proprietary and only available to Caris Life Sciences customers IRVING, Texas, March 9, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading patient-centric, ne

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by